Compare Franklin Resources, Inc. (BEN) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs Inovio Pharmaceuticals Inc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Franklin Resources, Inc. is far larger — about 215.8× Inovio Pharmaceuticals Inc's market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BEN | INO | |
|---|---|---|
Market Cap | $16.95B | $78.55M |
Sector | Financials | Health |
52-Week High | $35.77 | $2.87 |
52-Week Low | $21.18 | $0.66 |
Enterprise Value | $29.90B | $49.56M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.59, up 0.21% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026 (Business Wire, 2026-08-05), driven by strong inflows and diversification. Fundamentals show revenue growth to $8.77B in 2025 and a net income margin of 5.98%, though ROE remains low at 1.34%.
The outlook is positive with a consensus price target of $36.50 (22 analysts, August 2026) and recent momentum from private markets expansion. Key risks include volatile cash flows, with a net cash outflow of $835M in 2025, and competitive fee pressures. The stock offers upside potential but requires monitoring of margin sustainability and market-sensitive AUM growth.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
